UnitedHealth Group Incorporated's stock faces a steep decline amid leadership turmoil, regulatory pressures, and rising costs ...

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases. Surging medical costs and regulatory changes hit ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look ...

Davis Selected Advisers’ 13F portfolio value increased to $17.35B, with the number of holdings rising from 100 to 104. Learn ...